Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 13/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.56 |
| ▸ | ABCC1 | P33527 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | GBA1 | P04062 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391608 | 0.81 | ABCG2 (0.57) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL21980348 | 0.78 | ABCG2 (0.85) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL392277 | 0.71 | ABCG2 (0.70) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL21977560 | 0.69 | ABCG2 (1.00) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL14987901 | 0.67 | ABCG2 (0.76) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL16392215 | 0.66 | ABCG2 (0.61) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL390297 | 0.66 | ABCG2 (0.62) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL21979438 | 0.65 | ABCG2 (0.82) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL15658387 | 0.65 | PDE4B (1.00) | PDE4BPDE4D | |
| SCHEMBL15660397 | 0.65 | PDE4B (1.00) | PDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101626-B2 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |